Observation Of Short-Term Effects Of Endostar Combined With Chemotherapy Regimen For Advanced Non-Small Cell Lung Cancer

[Purpose] Endostar (YH-16) is a brand new recombined human vascular endothelial inhibitor developed by the scientists of PRC indecently. It plays a role in intervention of interaction between endothelial cell and cellular extra-matrix, preventing the construction of the vascular network and slowing down the rate of the malignant cell proliferation and the tumor growth by changing its amino acid sequence. It is targeted at the tumor cell, and has a synergistic effect with chemo-therapy. The current study is designed to get a full observation of the short-term effects and safety of Endostar combined with platinum based chemotherapy for advanced non-small cell lung cancer (NSCLC) and preparation for the large-scaled clinical research of IV stage.[Methods] Following Inclusion criteria,32 advanced NSCLC patients were select from the Respiratory Department of Zhongshan Hospital from 3/2007-5/2009. According to the treatment protocols, they were administrated the Endostar combined with chemotherapy. The data was collected, analyzed and compared according to the patients profile. And the response rate (RR), clinical benefit rate (CBR), quality of life, time to progression (TTP) and side reactions were evaluated.[Result]The RR is 18.8%(6/32), CBR 62.5%(20/32). Median TTP is 5.7 months, ranging from 1.4-12.2 months. RR is 50% and 4.5%(p<0.01) respectively in the group of squamous cell carcinoma and adenocarcinoma, with the median TTP 7. lmonths and 4.7 months, showing significant difference in statistics. RR is 13.6% and 10.0% (p>0.05) respectively in the group of naive and treated patients, and the CBR is 69.1% and 70%, while sharing the same median TTP of 5.6 months. RR is 9.1% and 20.0%(p>0.05) respectively in the group of smokers and non-smokers, and the CBR is 59.1% and 70%, with the median TTP of 6 months and 5.7 months. This profile witnesses the benefit of non-smokers but without statistic significance. The result is the same in female comparing with the male, and most of the female are non-smokers, due to the small sample, the profile did not get a further subdivision. During the administration, the study showed 14 side effects of G3/4, including the decrease of white blood cell with the incidence of 15.6%(5/32),28. 1% had the decrease of granulocyte (9/32),6.3% suffered the decrease of platele(2/32),3.1% had infections(1/32),3.1% complained about fatigue without specific reason and 3.1% was caught arrhythmia. No severe dyspnea and allergic shock is observed. Only one case was found the change of the T wave in electrocardiogram. And another on was diagnosed reversible myocardial ischemia and recovered while withdrawal the chemotherapy, with no abnormality in cTnT, CK and cardiac color ultrasound. One case was observed transient elevated of blood glucose. In the scale of quality of life,6 enjoyed the alleviation of the symptoms, 4 aggravated but without statistic significance.[Conclusion]Endostar gains obvious benefit in the group of squamous cell on NSCLC combined with chemotherapy, with tolerable side effects. The long-term effect need further evaluation.